- Dehydrocorydaline
-
- $0.00 / 25kg
-
2024-04-12
- CAS:30045-16-0
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 2000ton
- Dehydrocorydaline
-
- $0.00 / 20mg
-
2023-02-24
- CAS:30045-16-0
- Min. Order: 5mg
- Purity: ≥95%(HPLC)
- Supply Ability: 10 g
- Dehydrocorydaline
-
- $15.00 / 1KG
-
2021-07-13
- CAS:30045-16-0
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
|
| | Dehydrocorydaline Basic information |
| Product Name: | Dehydrocorydaline | | Synonyms: | 13-Methylpalmatine;dehydeocorydaline;Dehydrocorydaline;DEHYDROCORYDALINE98%;13-Methyl-2,3,9,10-tetramethoxy-5,6-dihydrodibenzo[a,g]quinolizinium;5,6-Dihydro-2,3,9,10-tetramethoxy-13-methyldibenzo[a,g]quinolizinium;Dibenzo[a,g]quinolizinium,5,6-dihydro-2,3,9,10-tetramethoxy-13-methyl-;acetate salt of Dehydrocorydaline | | CAS: | 30045-16-0 | | MF: | C22H24NO4 | | MW: | 0 | | EINECS: | | | Product Categories: | chemical reagent;pharmaceutical intermediate;phytochemical;reference standards from Chinese medicinal herbs (TCM).;standardized herbal extract | | Mol File: | 30045-16-0.mol |  |
| | Dehydrocorydaline Chemical Properties |
| Melting point | 170-173℃ | | storage temp. | Inert atmosphere,Room Temperature | | solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | | form | Cryst. | | Stability: | Hygroscopic |
| | Dehydrocorydaline Usage And Synthesis |
| Chemical Properties | Yellow needle crystal powder, soluble in methanol, ethanol, DMSO and other organic solvents, derived from Corydalis Corydalis, Yuanhu. | | Uses | Dehydrocordine has analgesic and sedative effects. It was used for content determination/identification/pharmacological experiments, etc. | | Definition | ChEBI: Dehydrocorydaline is an alkaloid. | | Biological Activity | Dehydrocorydaline (13-Methylpalmatine) is an alkaloid isolated from the traditional Chinese medicine Corydalis yanhusuo. It can enhance p38 MAPK activation and has anti-inflammatory and anti-cancer effects. Also Dehydrocorydaline has potent antimalarial effects and low cytotoxicity (cell viability > 90%), P. falciparum 3D7 strain (IC50=38 nM). | | in vitro | Dehydrocorydaline (0-200 μM) treatment significantly inhibits the growth of MCF-7 cells in a dose-dependent manner. The cell viability is decreased by approximate 40% after 24 h of 200 μM Dehydrocorydaline.
Dehydrocorydaline (0-200 μM) dose-dependently increases Bax protein expression and decreases Bcl-2 protein expression.
Dehydrocorydaline (0-200 μM) induces activation of caspase-7,-8 and the cleavage of PARP without affecting caspase-9.
| | in vivo | Dehydrocorydaline manifests a low acute toxicity with an LD 50 of about 277.5±19.0 mg/kg body weight in mice following oral administration and 21.1±1.4 mg/kg for intraperitoneal injection. < /p> | | target | | Bcl-2 < span> | Bax | Caspase-7 | Caspase-8 | PARP | |
| | Dehydrocorydaline Preparation Products And Raw materials |
| Raw materials | 6H-Dibenzo[a,g]quinolizine,5,8,13,13a-tetrahydro-2,3,9,10-tetramethoxy-13-methyl-, (13R,13aS)-rel--->6-BROMO-2,3-DIMETHOXY-BENZALDEHYDE-->Corydaline-->Water-->Ethanol-->6,7-DIMETHOXY-1,2,3,4-TETRAHYDROISOQUINOLINE-->Nitric acid-->MERCURIC ACETATE-->Iodine-->Acetic acid |
|